Conatus Pharmaceuticals (Conatus Pharmaceuticals) EPS (Basic) : $-0.30 (TTM As of Mar. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals EPS (Basic)?

Conatus Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2020 was $-0.10. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2020 was $-0.30.

Conatus Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2020 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2020 was $-0.30.

Conatus Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2020 was $-0.10. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2020 was -0.30.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Conatus Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Conatus Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conatus Pharmaceuticals EPS (Basic) Chart

Conatus Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EPS (Basic)

Get a 7-Day Free Trial

-1.30

-1.31

-0.61

-0.59

-0.34

Conatus Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
EPS (Basic)	Get a 7-Day Free Trial															-0.14	-0.02	-0.10	-0.08	-0.10

Conatus Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Conatus Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2019 is calculated as

Basic EPS (A: Dec. 2019 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-11.385	-	0)	/	33.169
	=	-0.34

Conatus Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2020 is calculated as

Basic EPS (Q: Mar. 2020 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.481	-	0)	/	33.170
	=	-0.10

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30

Conatus Pharmaceuticals (NAS:CNAT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Conatus Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Conatus Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127

Website

https://www.conatuspharma.com

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.